AFFIMED N V Stock (AFMDQ.US) Real-time Quotes - Financial Data - Analyst Ratings

Company Encyclopedia

AFFIMED N V

AFMDQ.US

1.930 T

AFMDQ.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update

BiotechnologyIndustry

Industry Ranking343/394

Industry medianC

Industry averageD

Score Analysis

Peer Comparison

Criteria
Rating
Profit ScoreD
- ROE-149.48%E
- Profit Margin-1241.26%E
- Gross Margin100.00%A
Growth ScoreE
- Revenue YoY-72.49%E
- Net Profit YoY40.34%B
- Total Assets YoY-65.04%E
- Net Assets YoY-76.29%E
Cash ScoreE
- Cash Flow Margin-8.06%D
- OCF YoY-72.49%E
Operating ScoreE
- Turnover0.07E
Debt ScoreD
- Gearing Ratio56.97%D

Valuation analysis

P/E

10Y

P/E

Industry Ranking

-/-

P/E
Price
High
Median
Low

P/B

10Y

P/B

Industry Ranking

-/-

P/B
Price
High
Median
Low

P/S

10Y

P/S

Industry Ranking

-/-

P/S
Price
High
Median
Low

Dividend Yield

10Y

Dividend Yield

Industry Ranking

-/-

Dividend Yield
Price
High
Median
Low

Institutional View & Shareholder

Analyst Ratings

Rating

Percentage

Price
--
Highest
--
Lowest
--

Shareholder

Ownership	%Owned	Share Chg	Report Date
Baillie Gifford & Co.	19.47%	No Change	30/11/2024
Gilde Healthcare Partners B.V.	4.96%	No Change	15/03/2024
Adi Hoess	1.95%	No Change	15/03/2024
Wolfgang Fischer	0.89%	No Change	15/03/2024
Denise Mueller	0.55%	No Change	15/03/2024
Arndt Justus Georg Schottelius	0.51%	No Change	15/03/2024
Andreas Harstrick	0.46%	No Change	15/03/2024
Angus W. Smith	0.4%	No Change	15/03/2024
Thomas O. Hecht	0.24%	No Change	15/03/2024
Bernhard R. M. Ehmer	0.13%	No Change	15/03/2024

News

Affimed Announces Receipt of Nasdaq Delisting Notice

Affimed N.V. has received a delisting notice from Nasdaq due to public interest concerns following its insolvency filing in Mannheim, Germany. The company's common shares will be suspended from trading on May 20, 2025, and a Form 25 Notification of Delisting will be filed with the U.S. Securities Exchange Commission. Affimed does not plan to appeal this decision, which reflects concerns about the company's compliance with Nasdaq listing requirements and the interests of existing securities holders.

GlobeNewswire·05/14/2025 18:45

GlobeNewswire·05/14/2025 18:45

Affimed NV Delays 2024 Annual Report Filing Due to Liquidity Concerns

Affimed N.V. has delayed its Annual Report filing for the financial year ended December 31, 2024, due to liquidity concerns. The company aims to enhance its liquidity position to ensure operational viability for at least twelve months from the expected issuance date. As of the end of 2024, Affimed's cash and investments were estimated at approximately €13.0 million, with a cash runway projected to last until the end of Q2 2025.

Reuters·05/02/2025 04:07

Reuters·05/02/2025 04:07

Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting

Affimed N.V. presented findings at the AACR Annual Meeting showing that higher exposure to AFM24 in patients with refractory non-small cell lung cancer (NSCLC) is linked to significantly improved response rates and progression-free survival. In a study of 72 patients, those with higher drug exposure had an objective response rate of 33.3% compared to 5.6% in the low-exposure group. The company plans to incorporate a 720 mg weekly dose in future trials to optimize treatment outcomes without increasing safety risks.

GlobeNewswire·04/29/2025 22:00

GlobeNewswire·04/29/2025 22:00

Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

Affimed N.V. has received a notice from Nasdaq indicating that its common shares have closed below the minimum bid price of $1.00 for 30 consecutive business days. The company has until October 13, 2025, to regain compliance. If unsuccessful, it may apply to transfer to the Nasdaq Capital Market for an additional 180 days. The notice does not affect the current listing or trading of shares. Affimed is focused on immuno-oncology and developing therapies to combat cancer.

GlobeNewswire·04/21/2025 18:30

GlobeNewswire·04/21/2025 18:30

Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting

MANNHEIM, Germany, March 25, 2025 ( GLOBE NEWSWIRE ) -- Affimed N.V. ( Nasdaq: AFMD ) , a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced an abstract on AFM24 dose optimization using exposure response analysis has ...

GlobeNewswire·03/26/2025 05:10

GlobeNewswire·03/26/2025 05:10